SaneVax, Inc.

The First International HPV Vaccine Information Clearinghouse

Reports summarize human papillomavirus research from University of Michigan

By 1 Comment

NewsRx

September 6, 2010

Investigators publish new data in the report ‘Examining future adolescent human papillomavirus vaccine uptake, with and without a school mandate.’ In this recent report published in the Journal of Adolescent Health, researchers in the United States conducted a study “To develop a model of adolescent (HPV) human papillomavirus vaccine utilization that explored future HPV vaccination rates, with and without a school mandate, for the vaccine at middle school entry. A dynamic, population-based, compartmental model was developed that estimated over a 50-year time horizon HPV vaccine uptake among female adolescents living in the United States.”

Vaccine suspensions and drug disasters has made 2010 a annus horribilis for Glaxo Smith Kline

By Leave a Comment

American Chronicle

by Christina England
September 7, 2010

GlaxoSmithKline the drug giants, have spent the last few days trying to stay off the bottom of the FTSE 100, especially after the UK’s Medicines and Healthcare Products Regulatory Agency said that it’s diabetes treatment Avandia should be pulled from sale, over concerns that it can lead to heart attacks in some patients. This came at a particularly difficult time for GlaxoSmithKline and was yet another nail in their coffin, as Pandemrix, their vaccine for the swine flu, is currently also under the magnifying glass, having been suspended by Finland, Sweden, Poland and Nepal, due to a growing number of reports of adverse reactions.

Last night the UK documentary series Panorama, revealed that despite warnings that the drug Avandia should be removed from the market, millions of prescriptions for the drug were still being written every day and doctors had been ignoring the advice given, by failing to warn patients about potential safety issues. The safety trials which had been studied by the agencies approving the drug, were shown to be substandard and it was revealed that it was GSK themselves who had carried out the safety trials showing only the ones that boosted favourable results. These revelations appeared to have caused GSK to finally hit the bottom of the FTSE with a massive thud, as shares plummeted 19.5p to 1,249p. This was despite their insistence as usual that both Avandia and Pandemrix were both safe and effective.

'We will continue to sell our patented drugs with India-specific pricing'

By 1 Comment

The Times of India

September 8, 2010

MSD India’s managing director KG Ananthakrishnan spoke to ET’s Khomba Singh on future strategy and shared his views on the Indian government’s proposals on contentious issues such as compulsory licensing, capping FDI in the sector and reviewing of certain sections of Indian patent laws. Excerpts:

Global drugmakers have lobbied hard for review of controversial Section 3(d) of Indian patent laws and patent linkages. MNCs, including Merck, are yet to publicly voice views on the proposal being evaluated by the government?

A longitudinal study of genital human papillomavirus infection in a cohort of closely followed adolescent women

By 1 Comment

PubMed.gov

J Infect Dis. 2005 Jan 15;191(2):182-92. Epub 2004 Dec 10.

Brown DR, Shew ML, Qadadri B, Neptune N, Vargas M, Tu W, Juliar BE, Breen TE, Fortenberry JD.

Division of Infectious Diseases, Indiana University School of Medicine, 545 Barnhill Dr., Emerson Hall, Rm. 435, Indianapolis, IN 46202, USA. darbrow@iupui.edu
Abstract

BACKGROUND: We performed a study to better characterize the natural history of genital human papillomavirus (HPV) infection in a cohort of closely followed adolescent women.

METHODS: A cohort of 60 adolescent women was followed over a 2.2-year period, on average. A median of 41.5 self-collected vaginal and clinician-obtained cervical swabs were obtained from each subject.

Prevalence of HPV Infection Among Females in the United States

By 1 Comment

JAMA

Eileen F. Dunne, MD, MPH; Elizabeth R. Unger, PhD, MD; Maya Sternberg, PhD; Geraldine McQuillan, PhD; David C. Swan, PhD; Sonya S. Patel, BS; Lauri E. Markowitz, MD

JAMA. 2007;297:813-819.

ABSTRACT

Context – Human papillomavirus (HPV) infection is estimated to be the most common sexually transmitted infection. Baseline population prevalence data for HPV infection in the United States before widespread availability of a prophylactic HPV vaccine would be useful.

Objective – To determine the prevalence of HPV among females in the United States.

Design, Setting, and Participants – The National Health and Nutrition Examination Survey (NHANES) uses a representative sample of the US noninstitutionalized civilian population. Females aged 14 to 59 years who were interviewed at home for NHANES 2003-2004 were examined in a mobile examination center and provided a self-collected vaginal swab specimen. Swabs were analyzed for HPV DNA by L1 consensus polymerase chain reaction followed by type-specific hybridization. Demographic and sexual behavior information was obtained from all participants.

News

Videos

Contact